Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Evusheld

- PMLiVE

AZ shutters R&D unit in India

Local reports says pharma company will transfer operations to UK and outsourcing partners

- PMLiVE

NICE backs Astellas’ Xtandi in prostate cancer

But company criticises restrictions imposed by HTA body for England

- PMLiVE

NICE set to extend MabThera recommendation

Says Roche’s drug can be used on NHS to treat two serious forms of vasculitis

- PMLiVE

AZ gets green light in EU for Xigduo diabetes combination

Wins approval for first line extension of Forxiga

- PMLiVE

NICE recommends Sanofi’s oral MS drug

Aubagio backed for NHS use in England and Wales

- PMLiVE

AZ’s Soriot upbeat on firm’s prospects

Says pharma company can return to growth by 2017

- PMLiVE

2013 – biotech boomed

The $10bn-plus strategic acquisition returned and pharma companies sought to replenish their pipelines

- PMLiVE

FDA clears BMS/AZ’s dapagliflozin at second attempt

Diabetes drug approved as companies look to end alliance

AZ agrees cancer alliance with Immunocore

Medimmune subsidiary will work with biotech on encouraging patient's immune system to tackle tumours

- PMLiVE

AstraZeneca expands personalised drug partnership with Horizon

Companies will research drug targets for targeted cancer treatments

- PMLiVE

AstraZeneca buys BMS out of diabetes alliance

Will spend up to $4.3bn to secure sole rights to Onglyza and Forxiga

- PMLiVE

AZ faces early competition to Nexium in the US

Korea's Hanmi and Amneal Pharmaceuticals launches first generic rival

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links